Abstract

BackgroundSirolimus has been confirmed to be effective for lymphangioleiomyomatosis (LAM), a rare multisystem neoplastic disease in women. The long-term effects of sirolimus treatment for LAM, however, are largely unknown. We aimed to analyze the long-term efficacy and safety of sirolimus therapy for LAM with 4-year follow-up.MethodsIn total, 142 sporadic LAM patients who took sirolimus for 1–4 years were retrospectively enrolled for this analysis. The variables used for analysis included pulmonary function tests, arterial blood gas analysis, 6-min walking distance (6MWD), St. George’s Respiratory Questionnaires (SGRQ) and serum vascular endothelial growth factor-D (VEGF-D) levels before and after the initiation of sirolimus therapy. The rates of change (slope) in those variables were calculated, and adverse events were also analyzed.ResultsIn total, 122, 83, 60 and 32 patients out of 142 were followed for 1, 2, 3 and 4 years respectively. Sirolimus treatment improved the change rate in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) compared with the data before treatment (FEV1, − 10 ± 15 vs. − 178 ± 36 ml/y, P < 0.001 and FVC, 54 ± 22 vs.-72 ± 68 ml/y, P < 0.05). In comparison to the baseline measurements, significant improvements were observed in FEV1 at the first year; FVC at 1–2 years; arterial oxygen levels, 6MWD, and SGRQ at 1–3 years; and VEGF-D at 1–4 years. Overall, all variables stabilized or improved during the 4 years of observation. Adverse events related to sirolimus were mild.ConclusionSirolimus therapy is effective at improving or stabilizing pulmonary function, oxygen levels, exercise capacity, and quality of life in patients with LAM for up to 4 years. VEGF-D is maintained at a lower level for 4 years after treatment. Adverse events related to sirolimus were mild.

Highlights

  • Sirolimus has been confirmed to be effective for lymphangioleiomyomatosis (LAM), a rare multisystem neoplastic disease in women

  • Oxygen levels, exercise capacity and quality of life Not surprisingly, in comparison to the pretreatment data, the posttreatment data showed that sirolimus significantly improved pulmonary function (FEV1, forced expiratory volume in 1 second (FEV1)%predicted, forced vital capacity (FVC), FVC%predicted, FEV1/FVC, Diffusion capacity for carbon monoxide (DLCO)), oxygen levels (PaO2, P(A-a)O2), 6 min walking distance (6MWD), St George Respiratory questionnaire (SGRQ) and vascular endothelial growth factor-D (VEGF-D) levels (Table 2)

  • Over a mean duration of 1.4 ± 0.5 years before the beginning of sirolimus therapy, the FEV1 decreased by 178 ± 36 ml per year (7.71% ± 1.20% predicted, P < 0.001), and the FVC decreased by − 72 ± 68 ml per year (− 4.11% ± 1.15% predicted, P < 0.001)

Read more

Summary

Methods

142 sporadic LAM patients who took sirolimus for 1–4 years were retrospectively enrolled for this analysis. The variables used for analysis included pulmonary function tests, arterial blood gas analysis, 6-min walking distance (6MWD), St. George’s Respiratory Questionnaires (SGRQ) and serum vascular endothelial growth factor-D (VEGF-D) levels before and after the initiation of sirolimus therapy. The rates of change (slope) in those variables were calculated, and adverse events were analyzed

Results
Conclusion
Background
Method
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call